NEW YORK (GenomeWeb News) - TriLink Biotechnologies, a maker of customized nucleic acid products, said today it has received a $100,000 Phase I Small Business Innovation Research grant from the National Institutes of Health to study a novel approach to PCR activation.
The NIH's National Institute of General Medical Sciences awarded the grant.
The company said its so-called Hot Start PCR method uses chemically modified triphosphates that inhibit DNA polymerase activity until a thermal activation step.
TriLink said this method has shown "significant promise” in reducing off-target amplification products in PCR.
The company plans to study ways to optimize the Hot Start effect and to continue to investigate its benchtop applications.
TriLink said it is preparing to launch its "first major novel PCR product," which resulted from an earlier SBIR grant.
TriLink CEO Richard Hogrefe said the company believes it will be able to launch a second product with “significant implications for the PCR market” by late 2008 as a result of the latest SBIR.